Estimates of the proportion of SARS-CoV-2 infected individuals in Sweden
Henrik Hult, Martina Favero

TL;DR
This paper presents a Bayesian SEIR model with a Gaussian process prior to estimate the proportion of SARS-CoV-2 infected individuals in Sweden, integrating death data and infection snapshots to improve regional estimates during the COVID-19 pandemic.
Contribution
It introduces a novel Bayesian SEIR modeling approach with time-varying contact rates and parameter sharing to estimate infection proportions across regions.
Findings
Estimated 13.5% infected in Stockholm by May 15, 2020
Infection estimates range from 2.5% to 15.6% in other regions
Parameter uncertainty affects cumulative infection estimates more than daily death predictions
Abstract
In this paper a Bayesian SEIR model is studied to estimate the proportion of the population infected with SARS-CoV-2, the virus responsible for COVID-19. To capture heterogeneity in the population and the effect of interventions to reduce the rate of epidemic spread, the model uses a time-varying contact rate, whose logarithm has a Gaussian process prior. A Poisson point process is used to model the occurrence of deaths due to COVID-19 and the model is calibrated using data of daily death counts in combination with a snapshot of the the proportion of individuals with an active infection, performed in Stockholm in late March. The methodology is applied to regions in Sweden. The results show that the estimated proportion of the population who has been infected is around 13.5% in Stockholm, by 2020-05-15, and ranges between 2.5% - 15.6% in the other investigated regions. In Stockholm where…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCOVID-19 epidemiological studies · COVID-19 Pandemic Impacts · SARS-CoV-2 and COVID-19 Research
